RecruitingNCT04425434

Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma


Sponsor

French Africa Pediatric Oncology Group

Enrollment

3,000 participants

Start Date

Nov 1, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and early implementation of this protocol of therapeutic recommendations for treatment.


Eligibility

Max Age: 18 Years

Inclusion Criteria4

  • Unilateral intraocular Retinoblastoma (RB)
  • Unilateral extraocular intraorbital (RB)
  • Bilateral intraocular (RB)
  • bilateral intraocular (RB) on one side and extraocular but intraorbital on the other side.

Exclusion Criteria8

  • Externalized tumor mass
  • massive extension to optic nerve up to optical channeltumor
  • intracranial extension leptomeninges
  • cerebral parenchyma
  • extension to regional lymph nodes and/or remote metastases.
  • cerebrospinal fluid involvement.
  • Trilateral RB
  • Incapacity to followed the whole treatement.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEROBSERVATIONAL

We will look at the outcome of the the children treated to see if the survival is improved when these therapeutic measures are followed.


Locations(7)

Hopital Yalgado Ouedraogo

Ouagadougou, Burkina Faso

CHU de Treichville à ABIDJAN

Abidjan, Côte d’Ivoire

CUK (Cliniques Universitaires de Kinshasa)

Kinshasa, Kinshasa City, Democratic Republic of the Congo

Cliniques Universitaires de Lubumbashi (CUL)

Lubumbashi, Democratic Republic of the Congo

HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona

Antananarivo, Ampefiloha, Madagascar

CHU Gabriel Touré (HGT)

Bamako, Mali

Hôpital Aristide Le Dantec,

Dakar, Senegal

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04425434


Related Trials